1159831-86-3

Basic information

• Product Name: 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid
• Synonyms: 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid
• CAS NO: 1159831-86-3
• Molecular Formula: C7H4BrN3O2
• Molecular Weight: 242.04
• EINECS: -0
• Mol File: 1159831-86-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 2.09±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.95±0.41(Predicted)
• CAS DataBase Reference: 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid(1159831-86-3)
• EPA Substance Registry System: 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid(1159831-86-3)

Safety Data

• Hazardous Substances Data: 1159831-86-3(Hazardous Substances Data)

Usage

General Description

6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is a chemical compound with a heterocyclic structure containing a pyridine and triazole ring, as well as a carboxylic acid group. 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is a potential building block in the synthesis of pharmaceuticals and agrochemicals due to its versatile reactivity and unique structure. It is also being studied for its potential biological activities, such as its antimicrobial, antifungal, and antiviral properties. Additionally, its bromine substituent adds further reactivity and potential for additional synthetic modifications. Overall, 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid shows promise as a valuable compound in the fields of medicinal and agricultural chemistry.

Relevant articles and documents

Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis

Retinol-binding protein 4 (RBP4) serves as a transporter for all-trans-retinol (1) in the blood, and it has been proposed to act as an adipokine. Elevated plasma levels of the protein have been linked to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD). Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice. We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in Abca4-/- knockout mice with concomitant normalization of complement system protein expression and reduction of bisretinoid formation within the retinal pigment epithelium. We describe herein the discovery of novel RBP4 antagonists 48 and 59, which reduce serum RBP4 levels by >80% in mice upon acute oral dosing. Furthermore, 59 demonstrated efficacy in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may also have therapeutic utility for the treatment of NAFLD.

SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARAITON AND USE

The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is C1, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is C1, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.